BioMarin Pharmaceutical | BMRN - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agios Pharmaceuticals USD 58.45M 169K 2025-12
Alnylam Pharmaceuticals USD 132.38M 585K 2025-12
Amgen USD 539M 1000K 2025-12
Bayer EUR 982.42M 0 2025-12
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 192.3M 201K 2025-12
Gilead Sciences USD 1.24B 1000K 2025-12
Incyte USD 198.46M 2.33M 2025-12
Insmed USD 214.26M 1.67M 2025-12
Ionis Pharmaceuticals USD 161.97M 836K 2025-12
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 100.1M 400K 2025-12
PTC Therapeutics USD 81.47M 1.54M 2025-12
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105.3M 1.1M 2025-09
Roche Holding CHF 795.62M 699.54K 2025-12
Sarepta Therapeutics USD 104.96M 196K 2025-12
Ultragenyx Pharmaceutical USD 96.44M 88K 2025-09
United Therapeutics USD 43.64M 740K 2025-12
Vertex Pharmaceuticals USD 254M 0 2025-12